参考文献/References:
[1]Zhang C,Liu H,Wang H,et al. The predictive value of potential hematological biomarkers in acute coronary syndrome[J]. Clin Lab,2019,65(10).doi:10.7754/Clin.Lab.2019.181232.
[2]Durmus E,Kivrak T,Gerin F,et al. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are predictors of heart failure[J]. Arq Bras Cardiol,2015,105(6):606-613.
[3]Bozduman F,Yildirim E,Cicek G,et al. Biomarkers of nondipper hypertension in prehypertensive and hypertensive patients[J]. Biomark Med,2019,13(5):371-378.
[4] Fioranelli M,Bottaccioli AG,Bottaccioli F,et al. Stress and inflammation in coronary artery disease:a review psychoneuroendocrineimmunology-based[J]. Front Immunol,2018,9:2031.
[5] Libby P,Pasterkamp G,Crea F,et al. Reassessing the mechanisms of acute coronary syndromes[J]. Circ Res,2019,124(1):150‐160.
[6] Chistiakov DA,Grechko AV,Myasoedova VA,et al. The role of monocytosis and neutrophilia in atherosclerosis[J]. J Cell Mol Med,2018,22(3):1366‐1382.
[7] Cheow ES,Cheng WC,Lee CN,et al. Plasma-derived extracellular vesicles contain predictive biomarkers and potential therapeutic targets for myocardial ischemic (MI) injury[J]. Mol Cell Proteomics,2016,15(8):2628‐2640.
[8] Verdoia M,Barbieri L,di Giovine G,et al. Neutrophil to lymphocyte ratio and the extent of coronary artery disease:results from a large cohort study[J]. Angiology,2016,67(1):75-82.
[9] Li XT,Fang H,Li D,et al. Association of platelet to lymphocyte ratio with in-hospital major adverse cardiovascular events and the severity of coronary artery disease assessed by the Gensini score in patients with acute myocardial infarction [J]. Chin Med J (Engl),2020,133(4):415-423.
[10] G?kta? MU,Akyol PY, Karakaya Z ,et al. Evaluation of white blood cell and neutrophil/lymphocyte ratio in acute coronary syndrome patients admitted to emergency department[J]. Biomed Res,2018,29(10):2009-2014.
[11] Akyel A,Yayla ?,Erat M,et al. Neutrophil-to-lymphocyte ratio predicts hemodynamic significance of coronary artery stenosis[J]. Anatol J Cardiol,2015,15(12):1002-1007
[12] Dur A,?smailo?lu Z ,Ismailova M ,et al.Relationships among markers of inflammation,neutrophil-to-lymphocyte ratio,and syntax severity score in the early phase of acute coronary syndrome[J]. Bezmialem Science,2017,5:56-60.
[13] Harun H ,Bahrun U,Darmawaty E. Platelet-lymphocyte ratio (PLR) markers in acute coronary syndrome[J]. Indones J Clin Pathol Med Lab,2016,23(1):7-11.
[14] Nedaa EE, Ayman AG, Mohamed AH, et al .The relation between platelet to lymphocyte ratio with severity and complexity of coronary heart disease in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention[J]. Med J Cairo Univ,2019,87(6):2033-2044.
[15] Celik T,Balta S,Mikhailidis DP,et al. The relation between no-reflow phenomenon and complete blood count parameters[J]. Angiology,2017,68(5):381-388.
[16] Allencherril J,Jneid H,Atar D,et al. Pathophysiology,diagnosis,and management of the no-reflow phenomenon[J]. Cardiovasc Drugs Ther,2019,33(5):589-597.
[17] Del Turco S,Basta G,de Caterina AR,et al. Different inflammatory profile in young and elderly STEMI patients undergoing primary percutaneous coronary intervention (PPCI):Its influence on no-reflow and mortality[J]. Int J Cardiol,2019,290:34-39.
[18] Ren F,Mu N,Zhang X,et al. Increased platelet-leukocyte aggregates are associated with myocardial no-reflow in patients with ST elevation myocardial infarction[J]. Am J Med Sci,2016,352(3):261-266.
[19] Kurtul A,Murat SN,Yarlioglues M,et al. Increased neutrophil-to-lymphocyte ratio predicts persistent coronary no-flow after wire insertion in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention[J]. Clinics (Sao Paulo),2015,70(1):34-40.
[20] Pinheiro MG,Araujo GN,Carpes CK,et al. Elevated neutrophil-to-lymphocyte ratio can predict procedural adverse events in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention[J]. Coron Artery Dis,2019 Jan,30(1):20-25.
[21] Emara A,Samy N,Farid W,et al. Value of platelet to lymphocytes ratio in predicting angiographic reflow after primary percutaneous coronary intervention in STEMI patient[J]. World J Cardiovasc Dis,2019,9:300-308.
[22] Yildiz A,Yuksel M,Oylumlu M,et al. The utility of the platelet-lymphocyte ratio for predicting no reflow in patients with ST-segment elevation myocardial infarction[J]. Clin Appl Thromb Hemost,2015,21(3):223-228．
[23] 张丽萍,王军,李世敬等. 血清炎性标志物对急性ST段抬高型心肌梗死患者冠状动脉侧支循环未形成的预测价值研究[J]. 临床误诊误治,2016,29:75-79.
[24] Serkan A,Aytac A,Muntecep A,et al. The relation of platelet-lymphocyte ratio and coronary collateral circulation in patients with non-ST segment elevation myocardial infarction[J]. Adv Interv Cardiol,2016,12,3 (45):224-230.
[25] Bolca O,Güng?r B,?zcan KS,et al. The neutrophil-to-lymphocyte ratio is associated with bare-metal stent restenosis in STEMI patients treated with primary PCI[J]. Coron Artery Dis,2015,26(5):402-408.
[26] Yilmaz S,Sen F,?nal S,et al. Usefulness of the platelet-to-lymphocyte ratio in predicting bare-metal stent restenosis[J]. Scand Cardiovasc J,2015,49(1):39-44.
[27] Bekler A,Erbag G,Sen H,et al. Predictive value of elevated neutrophil-lymphocyte ratio for left ventricular systolic dysfunction in patients with Non-ST elevated acute coronary syndrome[J]. Pak J Med Sci,2015,31(1):159-163.
[28] Bekler A,Gazi E,Y?lmaz M,et al. Could elevated platelet-lymphocyte ratio predict left ventricular systolic dysfunction in patients with non-ST elevated acute coronary syndrome?[J]. Anatol J Cardiol,2015,15:385-390.
[29] 叶飘,雷晓明. 入院首次中性粒细胞/淋巴细胞比值与急性心肌梗死患者院内主要不良心血管事件发生的相关性研究[J]. 广州医药,2018,49(5):13-17.
[30] Ozcan Cetin EH,Cetin MS,Aras D,et al. Platelet to lymphocyte ratio as a prognostic marker of in-hospital and long-term major adverse cardiovascular events in ST-segment elevation myocardial infarction[J]. Angiology,2016,67(4):336-345.
[31] ?i?ek G,A??kgoz SK,Bozbay M,et al. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio combination can predict prognosis in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention[J]. Angiology,2015,66(5):441-447.
相似文献/References:
[1]李润土,何泉.光学相干断层成像在急性冠脉综合征介入治疗中的应用[J].心血管病学进展,2019,(6):856.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.005]
LI Runtu,HE Quan.Application of Optical Coherent Tomography in Interventional Treatment of Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2019,(12):856.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.005]
[2]郑晓雪 季福绥.急性冠脉综合征患者发生急性肾损伤的临床进展[J].心血管病学进展,2019,(5):713.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.013]
ZHENG Xiaoxue,JI Fusui.Acute Kidney Injury in Patients with Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2019,(12):713.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.013]
[3]周小琳 何泉.替格瑞洛在急性冠脉综合征合并慢性肾脏病患者中的应用研究进展[J].心血管病学进展,2019,(5):718.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.014]
ZHOU Xiaolin,HE Quan.Ticagrelor in Acute Coronary Syndrome with Chronic Kidney Disease[J].Advances in Cardiovascular Diseases,2019,(12):718.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.014]
[4]吕俊兴 许海燕.急性冠脉综合征危险评分的研究进展[J].心血管病学进展,2019,(9):1224.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.010]
LU Junxing,XU Haiyan.Risk Scores of Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2019,(12):1224.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.010]
[5]吕颖 胡思宁 于波 贾海波.斑块侵蚀发病机制的最新研究进展[J].心血管病学进展,2020,(1):74.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.020]
LU Ying,HU Sining,YU Bo,et al.Pathogenic Mechanisms of Plaque Erosion[J].Advances in Cardiovascular Diseases,2020,(12):74.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.020]
[6]段继坤,林志,杨帆,等.斑块侵蚀引起的急性冠脉综合征的研究新进展[J].心血管病学进展,2020,(3):281.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.016]
DUAN Jikun,LIN Zhi,YANG Fan,et al.Acute Coronary Syndrome Caused by Plaque Erosion[J].Advances in Cardiovascular Diseases,2020,(12):281.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.016]
[7]陈凯磊 胡闻竹 苏冠华.P2Y12抑制剂与癌症风险的相关性研究进展[J].心血管病学进展,2020,(8):798.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.004]
CHEN Kailei,HU Wenzhu,SU Guanhua.Advances in Studies on the Correlation between P2Y12 Inhibitors and Cancer Risk[J].Advances in Cardiovascular Diseases,2020,(12):798.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.004]
[8]肖雨尘 赵仙先 马丽萍.急性冠脉综合征患者提前停服替格瑞洛现象的研究进展[J].心血管病学进展,2020,(11):1120.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
Acute Coronary Syndrome.Premature Ticagrelor Discontinuation in Patients with[J].Advances in Cardiovascular Diseases,2020,(12):1120.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
[9]魏倩 梁岩.高敏心肌肌钙蛋白在急性冠脉综合征患者中的临床应用进展[J].心血管病学进展,2021,(5):396.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.003]
[10]朱志伦 田乃亮.急性冠脉综合征患者抗血小板降阶治疗方案研究进展[J].心血管病学进展,2021,(6):534.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.014]
ZHU Zhilun,TIAN Nailiang.Advances in De-Escalation of Anti-Platelet Therapy in Patients with Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2021,(12):534.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.014]